| 臺大學術典藏 |
2022-04-14T23:27:49Z |
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
|
Tan, Ryan Shea Ying Cong; Ong, Whee Sze; Lee, Kyung Hun; Lim, Abner Herbert; Park, Seri; Park, Yeon Hee; CHING-HUNG LIN; YEN-SHEN LU; Ono, Makiko; Ueno, Takayuki; Naito, Yoichi; Onishi, Tatsuya; Lim, Geok Hoon; Tan, Su Ming; Lee, Han Byoel; Ryu, Han Suk; Han, Wonshik; Tan, Veronique Kiak Mien; Wong, Fuh Yong; Im, Seock Ah; Tan, Puay Hoon; Chan, Jason Yongsheng; Yap, Yoon Sim |
| 臺大學術典藏 |
2022-03-22T15:05:34Z |
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
|
YEN-SHEN LU; Im, Seock Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Cardoso, Fatima; Harbeck, Nadia; Hurvitz, Sara; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; De Laurentiis, Michelino; Im, Young Hyuck; Kuemmel, Sherko; El-Saghir, Nagi; O'Regan, Ruth; Gasch, Claudia; Solovieff, Nadia; Wang, Craig; Wang, Yongyu; Chakravartty, Arunava; Ji, Yan; Tripathy, Debu |
| 臺大學術典藏 |
2022-03-14T23:45:40Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen, Shin Cheh; Tseng, Ling Ming; Chang, King Jen; Huang, Ai Chu; Cheng, Kuo Chih; Yang, Karen; Wu, Hui Chen; Chao, Tsu Yi; Chang, Yuan Ching; Lin, Peng Chan; WEN-HUNG KUO; Kuo, Wen Lin; CHING-HUNG LIN; Chen, Huo Mu; Yeh, Dah Cherng; Liu, Liang Chih; Liu, Chun Yu; Wang, Ming Yang; Lo, Chiao; YEN-SHEN LU; CHIUN-SHENG HUANG |
| 臺大學術典藏 |
2022-03-10T06:15:01Z |
Genomic profiling of premenopausal HR+ and HER2�V metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia A.; Su F.; Solovieff N.; Im S.-A.; Sohn J.; Lee K.S.; Campos-Gomez S.; Jung K.H.; Colleoni M.; V?zquez R.V.; Franke F.; Hurvitz S.; Harbeck N.; Chow L.; Taran T.; Lorenc K.R.; Babbar N.; Tripathy D.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:01Z |
Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
|
Chang D.-Y.; Ma W.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU; Yap Y.-S.; Tamura K.; Fujiwara Y. |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:15:00Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer
|
Fasching P.A.; Delea T.E.; YEN-SHEN LU; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong A.; Kim H.-J. |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2022-03-10T06:14:58Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; YEN-SHEN LU; Chuang E.Y.; Thiery J.P.; Huang C.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-12-21T23:17:41Z |
Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2− advanced breast cancer
|
Fasching, Peter A.; Delea, Thomas E.; YEN-SHEN LU; De Boer, Richard; Hurvitz, Sara A.; Moynahan, Aaron; Chandiwana, David; Lanoue, Brad; Hu, Huilin; Thuerigen, Astrid; O’shaughnessy, Joyce |
| 臺大學術典藏 |
2021-11-21T23:19:52Z |
Genomic profiling of premenopausal HR+ and HER2– metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib
|
Bardia, Aditya; Su, Fei; Solovieff, Nadia; Im, Seock Ah; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Jung, Kyung Hae; Colleoni, Marco; Vázquez, Rafael Villanueva; Franke, Fabio; Hurvitz, Sara; Harbeck, Nadia; Chow, Louis; Taran, Tetiana; Lorenc, Karen Rodriguez; Babbar, Naveen; Tripathy, Debu; YEN-SHEN LU |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
|
YEN-SHEN LU; Wong, Andrea; Kim, Hee Jeong |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
YEN-SHEN LU; Yeo, Winnie; Yap, Yoon Sim; Park, Yeon Hee; Tamura, Kenji; Li, Huiping; Cheng, Rebecca |
| 臺大學術典藏 |
2021-10-21T23:28:16Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai, Ming Shen; Feng, Yin Hsun; Chen, Shang Wen; Masuda, Norikazu; Yau, Thomas; Chen, Shou Tung; YEN-SHEN LU; Yap, Yoon Sim; Ang, Peter C.S.; Chu, Sung Chao; Kwong, Ava; Lee, Keun Seok; Ow, Samuel; Kim, Sung Bae; Lin, Johnson; Chung, Hyun Cheol; Ngan, Roger; Kok, Victor C.; Rau, Kun Ming; Sangai, Takafumi; Ng, Ting Ying; Tseng, Ling Ming; Bryce, Richard; Bebchuk, Judith; Chen, Mei Chieh; Hou, Ming Feng |
| 臺大學術典藏 |
2021-09-14T23:19:03Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
CHING-HUNG LIN; RUBY YUN-JU HUANG; TZU-PIN LU; KUAN-TING KUO; Lo, Ko Yun; Chen, Ching Hsuan; Chen, I. Chun; YEN-SHEN LU; Chuang, Eric Y.; Thiery, Jean Paul; CHIUN-SHENG HUANG; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-15T00:08:34Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen, I. Chun; Hu, Fu Chang; CHING-HUNG LIN; Huang, Shu Min; Chang, Dwan Ying; ANN-LII CHENG; YEN-SHEN LU |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives
|
Chang, Dwan Ying; Ma, Wei Li; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-21T23:14:58Z |
Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs
|
Hata, Tomomi; Nakamura, Kenichi; Yonemori, Kan; Noguchi, Emi; Watanabe, Makiko; Sohn, Joohyuk; YEN-SHEN LU; Yap, Yoon Sim; Tamura, Kenji; Fujiwara, Yasuhiro |
| 臺大學術典藏 |
2021-03-10T02:36:33Z |
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
|
Harbeck N.;Franke F.;Villanueva-Vazquez R.;Yen-Shen Lu;Tripathy D.;Chow L.;Babu G.K.;Im Y.-H.;Chandiwana D.;Gaur A.;Lanoue B.;Rodriguez-Lorenc K.;Bardia A.; Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival
|
Chen T.W.-W.;Jan I.-S.;Chang D.-Y.;Lin C.-H.;Chen I.-C.;Chen H.-M.;Cheng A.-L.;Yen-Shen Lu; Chen T.W.-W.; Jan I.-S.; Chang D.-Y.; Lin C.-H.; Chen I.-C.; Chen H.-M.; Cheng A.-L.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components
|
Lien H.-C.; Lee Y.-H.; Chen I.-C.; Lin C.-H.; Chen T.W.-W.; Lu Y.-T.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Response to Sung, Rosenberg, and Yang
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)
|
Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; Lin C.-H.; YEN-SHEN LU; Wo A.M. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.;Chang S.-H.;Kuo W.-H.;Kuo C.-H.;Li S.-Y.;Wang M.-Y.;Chang D.-Y.;Yen-Shen Lu;Huang C.-S.;Cheng A.-L.;Lin C.-H.;Chen P.-C.; Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; YEN-SHEN LU; Huang C.-S.; Cheng A.-L.; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1
|
Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. |
| 臺大學術典藏 |
2021-03-03T10:26:44Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
Yen-Shen Lu; Lee, Keun Seok; Chao, Tsu Yi; Tseng, Ling Ming; Chitapanarux, Imjai; Chen, Shin Cheh; Liu, Chien Ting; Sohn, Joohyuk; Kim, Jee Hyun; Chang, Yuan Ching; Yang, Youngsen; Shotelersuk, Kanjana; Jung, Kyung Hae; Valenti, Roberta; Slader, Cassandra; Gao, Melissa; Park, Yeon Hee |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
| 臺大學術典藏 |
2021-02-02T09:21:43Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid, Peter; Sablin, Marie Paule; Bergh, Jonas; Im, Seock Ah; Yen-Shen Lu; Martínez, Noelia; Neven, Patrick; Lee, Keun Seok; Morales, Serafín; Pérez-Fidalgo, J. Alejandro; Adamson, Douglas; Gonçalves, Anthony; Prat, Aleix; Jerusalem, Guy; Schlieker, Laura; Espadero, Rosa Maria; Bogenrieder, Thomas; Huang, Dennis Chin Lun; Crown, John; Cortés, Javier |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Cheng A.-L.;Chang K.-J;Chen M.M;Bu C.-F;Yen-Shen Lu;Chao T.-Y;Huang C.-S;Hsu C; Hsu C; Huang C.-S; Chao T.-Y; YEN-SHEN LU; Bu C.-F; Chen M.M; Chang K.-J; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Basal levels and patterns of anticancer drug-induced activation of nuclear factor-�eB (NF-�eB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells
|
Cheng A.-L.;Gao M;Liao C.-M;Lai G.-M;Yen-Shen Lu;Yeh P.-Y;Chuang S.-E; Chuang S.-E; Yeh P.-Y; YEN-SHEN LU; Lai G.-M; Liao C.-M; Gao M; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer
|
Tripathy D; Rugo H; Park J; Hwang S; Kuerer H; Sudilovsky D; YEN-SHEN LU; Hylton N.; Partridge S; Kaplan E; Hylton N.;Yen-Shen Lu;Sudilovsky D;Kuerer H;Hwang S;Park J;Rugo H;Tripathy D;Partridge S;Kaplan E;Esserman L; Esserman L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Recent advances in the management of primary breast cancers
|
Huang C.-S.;Kuo S.-H;Yen-Shen Lu; YEN-SHEN LU; Kuo S.-H; Huang C.-S. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma
|
Cheng A.-L.;Hsiao C.-H;Yen-Shen Lu;Yeh K.-H; Yeh K.-H; YEN-SHEN LU; Hsiao C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Yen-Shen Lu;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Yang C.H;Cheng A.L.; Yeh K.H; YEN-SHEN LU; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; Yang C.H; Cheng A.L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI
|
Tseng W.-Y.I.;Yen-Shen Lu;Chen J.-H;Liu Y.-J;Huang C.-S;Chang Y.-C; Chang Y.-C; Huang C.-S; Liu Y.-J; Chen J.-H; YEN-SHEN LU; Tseng W.-Y.I. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-�eB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa
|
Yen-Shen Lu;Yeh P.-Y;Chuang S.-E;Gao M;Kuo M.-L;Cheng A.-L.; YEN-SHEN LU; Yeh P.-Y; Chuang S.-E; Gao M; Kuo M.-L; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Kuo M.-L; Kuo S.-H; Cheng A.-L.; Yeh K.-H; Yeh P.-Y; Lien H.-C; YEN-SHEN LU; Yen-Shen Lu;Lien H.-C;Yeh P.-Y;Yeh K.-H;Kuo M.-L;Kuo S.-H;Cheng A.-L. |
